Literature DB >> 7284993

Adriamycin-activated macrophages as tumor growth inhibitors.

J S Haskill.   

Abstract

Flow cytometry has been used to study the influence of Adriamycin- and Corynebacterium parvum-elicited cytostatic macrophages on the cell cycle of HeLa cells. Macrophages harvested from the peritoneal cavity of mice given i.p. injections of Adriamycin retain cytostatic activity for 3 to 4 days in vivo. Many of these macrophages fluoresced with the red emission spectra characteristic of Adriamycin. The decline in the presence of macrophages exhibiting red fluorescent cytoplasmic particles paralleled the loss in cytostatic activity. Drug-induced cytostatic macrophages exhibited at least as high a level of growth inhibition as did C. parvum-activated cells. In contrast to the apparent G1 block of HeLa cells which resulted from interaction wih C. parvum-activated macrophages. Adriamycin-stimulated macrophages inhibited growth in the G2-M phase characteristic of the free drug. Multiple freeze-thaw cycles removed all activity from C. parvum macrophages but had no influence on the Adriamycin-elicited effector cell activity. The data suggest that in vivo drug storage by macrophages may represent an important step in tumor cell destruction by Adriamycin.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7284993

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Enhanced susceptibility of target KMT-17 cells to activated macrophages by treatment with the antitumor agent bleomycin.

Authors:  Z Y Xu; M Hosokawa; K Morikawa; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

2.  Cancer chemotherapeutics as immunomodulators.

Authors:  F Spreafico; A Vecchi; F Colotta; A Montovani
Journal:  Springer Semin Immunopathol       Date:  1985

3.  Mechanisms and management of doxorubicin cardiotoxicity.

Authors:  Y Shi; M Moon; S Dawood; B McManus; P P Liu
Journal:  Herz       Date:  2011-06       Impact factor: 1.443

4.  Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule.

Authors:  Hazem Ghebeh; Cynthia Lehe; Eman Barhoush; Khaldoon Al-Romaih; Asma Tulbah; Monther Al-Alwan; Siti-Faujiah Hendrayani; Pulicat Manogaran; Ayodele Alaiya; Taher Al-Tweigeri; Abdelilah Aboussekhra; Said Dermime
Journal:  Breast Cancer Res       Date:  2010-07-13       Impact factor: 6.466

5.  Phylogenetic origin of LI-cadherin revealed by protein and gene structure analysis.

Authors:  R Jung; M W Wendeler; M Danevad; H Himmelbauer; R Gessner
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

6.  Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation.

Authors:  Hiroaki Tanaka; Hironori Matsushima; Akiko Nishibu; Björn E Clausen; Akira Takashima
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

7.  The synergistic tumoricidal activity of anticancer drugs and oxidative burst-triggered macrophages.

Authors:  S Marcovitch; Y Keisari
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

Review 8.  Macrophages and neoplasms: new insights and their implication in tumor immunobiology.

Authors:  R Evans
Journal:  Cancer Metastasis Rev       Date:  1982       Impact factor: 9.264

9.  Adriamycin-induced activation of NK activity may initially involve LAF production.

Authors:  S A Cohen; D Salazar; J Wicher
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

10.  Systemic activation of macrophages by liposome-entrapped muramyl tripeptide in mice pretreated with the chemotherapeutic agent adriamycin.

Authors:  G Hisano; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.